Eli Lilly and (LLY) EBITDA Margin: History & Chart

Eli Lilly and Company(LLY)

Drug Manufacturers - General · Indianapolis, IN

$1,144.98+6.69 (+0.59%)

Delayed quote: Sep 15, 2026, 10:15 AM EDT

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Indianapolis, IN

50,000 employees

www.lilly.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: David A. Ricks

View full financials

LLY EBITDA Margin Metrics

EBITDA MARGIN

47.96%

EBITDA MARGIN AVG TTM

46.83%

EBITDA MARGIN AVG 3Y

44.08%

EBITDA MARGIN AVG 5Y

39.75%

EBITDA MARGIN AVG 10Y

35.44%

EBITDA MARGIN AVG 15Y

32.83%

EBITDA MARGIN AVG 20Y

32.54%

CURRENT VS TTM AVG

+2.41%

CURRENT VS 3Y AVG

+8.80%

CURRENT VS 5Y AVG

+20.64%

CURRENT VS 10Y AVG

+35.32%

CURRENT VS 15Y AVG

+46.11%

CURRENT VS 20Y AVG

+47.39%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Eli Lilly and Company (LLY)	$1.08T	47.96%	46.83%	44.08%	39.75%
Johnson & Johnson (JNJ)vs ›	$632.60B	35.14%	34.17%	34.90%	34.70%
AbbVie Inc. (ABBV)vs ›	$460.11B	46.16%	38.63%	40.64%	41.43%
Merck & Co., Inc. (MRK)vs ›	$353.58B	45.17%	41.84%	33.12%	31.32%
Roche Holding AG (RHHBY)vs ›	$347.35B	34.51%	30.75%	31.14%	33.13%
UnitedHealth Group Incorporated (UNH)vs ›	$343.08B	5.21%	7.15%	8.47%	8.86%
AstraZeneca PLC (AZN)vs ›	$252.17B	33.16%	30.52%	27.50%	25.68%
Thermo Fisher Scientific Inc. (TMO)vs ›	$233.57B	24.44%	24.78%	25.35%	27.67%
Amgen Inc. (AMGN)vs ›	$202.99B	43.12%	40.78%	43.34%	44.32%
Novo Nordisk A/S (NVO)vs ›	$189.06B	48.42%	49.59%	48.46%	47.82%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Eli Lilly and Company (LLY)

$1.08T

47.96%

46.83%

44.08%

39.75%

Johnson & Johnson (JNJ)vs ›

$632.60B

35.14%

34.17%

34.90%

34.70%

AbbVie Inc. (ABBV)vs ›

$460.11B

46.16%

38.63%

40.64%

41.43%

Merck & Co., Inc. (MRK)vs ›

$353.58B

45.17%

41.84%

33.12%

31.32%

Roche Holding AG (RHHBY)vs ›

$347.35B

34.51%

30.75%

31.14%

33.13%

UnitedHealth Group Incorporated (UNH)vs ›

$343.08B

5.21%

7.15%

8.47%

8.86%

AstraZeneca PLC (AZN)vs ›

$252.17B

33.16%

30.52%

27.50%

25.68%

Thermo Fisher Scientific Inc. (TMO)vs ›

$233.57B

24.44%

24.78%

25.35%

27.67%

Amgen Inc. (AMGN)vs ›

$202.99B

43.12%

40.78%

43.34%

44.32%

Novo Nordisk A/S (NVO)vs ›

$189.06B

48.42%

49.59%

48.46%

47.82%

EBITDA Margin FAQ

What is the EBITDA margin for Eli Lilly and Company (LLY)?

The EBITDA margin for LLY stock is 47.96%.

Is Eli Lilly and Company's EBITDA margin high or low?

The EBITDA margin of 47.96% is 21% above its 5-year average of 39.75%, near the high end of its 5-year range (27.99%–50.32%).

What is the TTM average EBITDA margin for Eli Lilly and Company (LLY)?

The TTM average EBITDA margin for LLY stock is 46.83%.

What is the 3Y average EBITDA margin for Eli Lilly and Company (LLY)?

The 3Y average EBITDA margin for LLY stock is 44.08%.

What is the 5Y average EBITDA margin for Eli Lilly and Company (LLY)?

The 5Y average EBITDA margin for LLY stock is 39.75%.

What is the 10Y average EBITDA margin for Eli Lilly and Company (LLY)?

The 10Y average EBITDA margin for LLY stock is 35.44%.

What is the 15Y average EBITDA margin for Eli Lilly and Company (LLY)?

The 15Y average EBITDA margin for LLY stock is 32.83%.

What is the 20Y average EBITDA margin for Eli Lilly and Company (LLY)?

The 20Y average EBITDA margin for LLY stock is 32.54%.

DATE	EBITDA MARGIN
2026-06-30	41.40%
2026-03-31	47.27%
2025-12-31	46.28%
2025-09-30	50.32%
2025-06-30	48.88%
2025-03-31	46.13%
2024-12-31	46.42%
2024-09-30	43.85%
2024-06-30	42.76%
2024-03-31	35.77%
2023-12-31	38.28%
2023-09-30	41.61%
2023-06-30	32.54%
2023-03-31	29.84%
2022-12-31	35.37%
2022-09-30	34.58%
2022-06-30	32.27%
2022-03-31	39.68%
2021-12-31	36.46%
2021-09-30	37.11%
2021-06-30	27.99%
2021-03-31	30.90%
2020-12-31	37.00%
2020-09-30	32.26%
2020-06-30	32.71%
2020-03-31	34.49%
2019-12-31	31.81%
2019-09-30	33.75%
2019-06-30	32.30%
2019-03-31	31.78%
2018-12-31	30.18%
2018-09-30	35.69%
2018-06-30	37.14%
2018-03-31	36.90%
2017-12-31	19.16%
2017-09-30	28.10%
2017-06-30	29.36%
2017-03-31	28.78%
2016-12-31	24.28%
2016-09-30	26.62%
2016-06-30	25.07%
2016-03-31	25.34%
2015-12-31	20.22%
2015-09-30	27.46%
2015-06-30	26.59%
2015-03-31	26.84%
2014-12-31	23.86%
2014-09-30	21.24%
2014-06-30	25.02%
2014-03-31	25.94%
2013-12-31	23.15%
2013-09-30	32.80%
2013-06-30	32.55%
2013-03-31	32.58%
2012-12-31	27.08%
2012-09-30	27.73%
2012-06-30	27.93%
2012-03-31	31.97%
2011-12-31	25.72%
2011-09-30	32.03%
2011-06-30	33.21%
2011-03-31	35.80%
2010-12-31	30.17%
2010-09-30	37.09%
2010-06-30	37.01%
2010-03-31	36.62%
2009-12-31	28.79%
2009-09-30	35.88%
2009-06-30	35.95%
2009-03-31	40.82%
2008-12-31	34.34%
2008-09-30	33.31%
2008-06-30	30.67%
2008-03-31	32.16%
2007-12-31	28.56%
2007-09-30	32.17%
2007-06-30	32.73%
2007-03-31	32.60%
2006-12-31	29.00%
2006-09-30	32.71%
2006-06-30	31.10%
2006-03-31	33.10%
2005-12-31	31.10%
2005-09-30	31.03%
2005-06-30	28.54%
2005-03-31	28.72%
2004-12-31	30.50%
2004-09-30	31.30%
2004-06-30	29.68%
2004-03-31	31.46%
2003-12-31	28.75%
2003-09-30	34.46%
2003-06-30	32.49%
2003-03-31	33.52%
2002-12-31	33.58%
2002-09-30	36.80%

DATE

EBITDA MARGIN

2026-06-30

41.40%

2026-03-31

47.27%

2025-12-31

46.28%

2025-09-30

50.32%

2025-06-30

48.88%

2025-03-31

46.13%

2024-12-31

46.42%

2024-09-30

43.85%

2024-06-30

42.76%

2024-03-31

35.77%

2023-12-31

38.28%

2023-09-30

41.61%

2023-06-30

32.54%

2023-03-31

29.84%

2022-12-31

35.37%

2022-09-30

34.58%

2022-06-30

32.27%

2022-03-31

39.68%

2021-12-31

36.46%

2021-09-30

37.11%

2021-06-30

27.99%

2021-03-31

30.90%

2020-12-31

37.00%

2020-09-30

32.26%

2020-06-30

32.71%

2020-03-31

34.49%

2019-12-31

31.81%

2019-09-30

33.75%

2019-06-30

32.30%

2019-03-31

31.78%

2018-12-31

30.18%

2018-09-30

35.69%

2018-06-30

37.14%

2018-03-31

36.90%

2017-12-31

19.16%

2017-09-30

28.10%

2017-06-30

29.36%

2017-03-31

28.78%

2016-12-31

24.28%

2016-09-30

26.62%

2016-06-30

25.07%

2016-03-31

25.34%

2015-12-31

20.22%

2015-09-30

27.46%

2015-06-30

26.59%

2015-03-31

26.84%

2014-12-31

23.86%

2014-09-30

21.24%

2014-06-30

25.02%

2014-03-31

25.94%

2013-12-31

23.15%

2013-09-30

32.80%

2013-06-30

32.55%

2013-03-31

32.58%

2012-12-31

27.08%

2012-09-30

27.73%

2012-06-30

27.93%

2012-03-31

31.97%

2011-12-31

25.72%

2011-09-30

32.03%

2011-06-30

33.21%

2011-03-31

35.80%

2010-12-31

30.17%

2010-09-30

37.09%

2010-06-30

37.01%

2010-03-31

36.62%

2009-12-31

28.79%

2009-09-30

35.88%

2009-06-30

35.95%

2009-03-31

40.82%

2008-12-31

34.34%

2008-09-30

33.31%

2008-06-30

30.67%

2008-03-31

32.16%

2007-12-31

28.56%

2007-09-30

32.17%

2007-06-30

32.73%

2007-03-31

32.60%

2006-12-31

29.00%

2006-09-30

32.71%

2006-06-30

31.10%

2006-03-31

33.10%

2005-12-31

31.10%

2005-09-30

31.03%

2005-06-30

28.54%

2005-03-31

28.72%

2004-12-31

30.50%

2004-09-30

31.30%

2004-06-30

29.68%

2004-03-31

31.46%

2003-12-31

28.75%

2003-09-30

34.46%

2003-06-30

32.49%

2003-03-31

33.52%

2002-12-31

33.58%

2002-09-30

36.80%

EBITDA Margin: 47.96%

LLY EBITDA Margin

LLY Average EBITDA Margin Chart

LLY Current vs Average EBITDA Margin Chart

LLY EBITDA Margin Metrics

LLY Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

LLY EBITDA Margin History

Related Metrics